Physician profile
Ruby R Turner
NPI 1821069733
$1,244.65
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $447 · 2022: $731 · 2023: $46.09 · 2024: $20.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $151.85 | 2022 | |
| Rigel Pharmaceuticals, INC. | $129.24 | 2021-2022 | |
| Amgen INC. | $119.80 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $89.99 | 2021-2022 | |
| Lilly USA, LLC | $65.02 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $51.45 | 2021 | |
| Pharmacosmos Therapeutics INC. | $50.10 | 2021 | |
| Incyte Corporation | $49.48 | 2021-2022 | |
| Beigene USA, INC. | $47.52 | 2021-2022 | |
| Seagen INC. | $41.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.98 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $38.95 | 2021-2022 | |
| Eisai INC. | $34.75 | 2022 | |
| Abbvie INC. | $33.59 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $32.80 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $28.29 | 2022 | |
| Genentech USA, INC. | $28.00 | 2022 | |
| Novo Nordisk INC | $24.12 | 2023 | Wegovy |
| Genzyme Corporation | $22.57 | 2022 | |
| Pfizer INC. | $21.97 | 2023 | |
| Karyopharm Therapeutics INC. | $20.79 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.08 | 2024 | Rexulti |
| Gilead Sciences, INC. | $19.66 | 2022 | |
| Daiichi Sankyo INC. | $18.94 | 2021 | |
| Servier Pharmaceuticals LLC | $18.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.08 | 2022 | |
| G1 Therapeutics, INC. | $14.60 | 2022 | |
| Morphosys, US INC. | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.